AnaptysBio is a clinical stage biotechnology company developing antibody product candidates. Etokimab, the company's anti-IL-33 antibody drug candidate, inhibits the activity of the interleukin-33 cytokine that is applicable to the treatment of atopic inflammatory disorders, such as moderate-to-severe atopic dermatitis, eosinophilic asthma, chronic rhinosinusitis with nasal polyps, and potentially other allergic conditions. ANB019 inhibits the interleukin-36 receptor, for the treatment of rare inflammatory diseases including generalized pustular psoriasis and palmoplantar pustulosis. The company's wholly-owned pipeline includes anti-inflammatory checkpoint receptor modulator antibodies.

Codexis discovers, develops and sells proteins to its clients. The company has two segments: Performance Enzymes, which uses its technology to develop enzymes for customers using next generation sequencing and polymerase chain reaction for in vitro molecular diagnostic and molecular biology research applications; and Novel Biotherapeutics, in which it has announced a global development, option and license agreement with Societe des Produits Nestle S.A. to develop CDX-6114, its own orally administrable enzyme therapeutic candidate for the potential treatment of phenylketonuria. The company's products include protein catalysts, chemical intermediates and Codex? biocatalyst panels and kits.

Re/Max Holdings is a holding company. The company's only business is to act as the sole manager of RMCO, LLC. The company is a franchisor in the real estate industry, franchising real estate brokerages globally under the RE/MAX (RE/MAX) brand, and mortgage brokerages within the U.S. under the Motto Mortgage (Motto) brand. RE/MAX and Motto are fully franchised - the company does not own any of the brokerages that operate under these brands. All of the RE/MAX branded brokerage office locations are being operated by franchisees. The company operates under the following three segments: RE/MAX Franchising, Motto Franchising and booj.